Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Key Highlights
- ➤Acrivon (ACRV) acquired Phase 2-ready oral JAK1 inhibitor ACR-525 from Aqilion
- ➤ACR-525 targets eosinophilic esophagitis as its first potential indication
- ➤Acquisition includes a preclinical PKCθ inhibitor program and associated intellectual property
- ➤Acrivon paid undisclosed cash with no future royalties or milestone obligations
- ➤AP3 profiling found ACR-525 highly selective versus six approved JAK inhibitors and dupilumab
Expert Statements
Peter Blume-Jensen, Chief executive officer, president and co-founder of Acrivon Therapeutics
“This transaction is a pivotal step in expanding Acrivon’s AI-driven AP3 precision medicine platform beyond oncology establishing I&I as an additional strategic pillar for our company.”
Peter Blume-Jensen, Chief executive officer, president and co-founder of Acrivon Therapeutics
“As previously communicated, I&I is of high interest to us, given the high unmet need and general lack of recurrent genetic alterations.”
Peter Blume-Jensen, Chief executive officer, president and co-founder of Acrivon Therapeutics
“The ability of AP3 to quantify the cellular, disease-driving mechanisms without relying on genetic alterations and the wide usage of biopsies and biomarker-based clinical endpoints in I&I disorders, make AP3 particularly well-suited for this disease area.”
Peter Blume-Jensen, Chief executive officer, president and co-founder of Acrivon Therapeutics
“ACR-525 broadens our clinical stage pipeline as a promising Phase 2-ready I&I program with encouraging Phase 1 data, clinical evidence of selective JAK1 engagement, and one of two oral formulations purpose-built for patients with EoE, a devastating disease of rapidly increasing incidence.”
Peter Blume-Jensen, Chief executive officer, president and co-founder of Acrivon Therapeutics
“Longer-term, we believe ACR-525 has broad potential in IBD and broadly across autoimmune and inflammatory diseases.”
Peter Blume-Jensen, Chief executive officer, president and co-founder of Acrivon Therapeutics
“We believe the PKCθ inhibitor preclinical program can be optimized through our AP3 platform and potentially developed as part of an effective combination strategy.”
Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease
As part of Acrivon’s due diligence, extensive AP3 profiling against approved JAK inhibitors and dupilumab revealed ACR-525 as a highly-selective, potentially best-in-class JAK1 inhibitor
Get started
Create a free account to read the full story.